Nimodipine for injection

Pharmacology and Toxicology Nimodipine is a Ca2 channel blocker. Under normal circumstances, the contraction of smooth muscle depends on the entry of Ca2 into the cell, causing the depolarization of the transmembrane current. Nimodipine achieves the purpose of relieving vasospasm by effectively preventing Ca2 from entering the cell and inhibiting the contraction of smooth muscle. Animal experiments have shown that the effect of nimodipine on cerebral arteries is much stronger than that on arteries in other parts of the body, and because it has a high lipophilicity, it is easy to pass through the blood-brain barrier. When used for the treatment of subarachnoid hemorrhage, the concentration in cerebrospinal fluid can reach 12.5ng/ml. It can be inferred that it can be used clinically to prevent vasospasm after subarachnoid hemorrhage, but the mechanism of action of this drug in human application is still unclear. In addition, it also has the effect of protecting and promoting memory and promoting intellectual recovery. Therefore, it can selectively act on cerebral vascular smooth muscle, dilate cerebral blood vessels, increase cerebral blood flow, and significantly reduce ischemic brain damage caused by vasospasm.

Nimodipine.

This product is white or slightly yellow loose block or powder.

It is suitable for improving blood circulation in the recovery period of cerebral vasospasm after subarachnoid hemorrhage of various reasons and acute cerebrovascular disease.

Take 4 mg of nimodipine for injection, dissolve it with an appropriate amount of 5% glucose or glucose saline, inject it into 250 ml or 500 ml of 5% glucose or glucose saline, mix well and immediately drip it intravenously. For patients with an estimated weight of less than 70 kg or unstable blood pressure, 0.5 mg of nimodipine can be administered every hour for the first 2 hours of treatment. If the tolerance is good, especially when there is no significant drop in blood pressure, the dose can be increased to 1 mg of nimodipine after 2 hours. For patients with an estimated weight of more than 70 kg, the dose should start with 1 mg of nimodipine per hour. If there is no discomfort after 2 hours, it can be increased to 2 mg. For patients with adverse reactions, it is necessary to reduce the dose or stop treatment. Medication course: Preventive medication: Intravenous treatment should be started within 4 days after bleeding and continued during the maximum risk period of vasospasm, that is, until 10-14 days after subarachnoid hemorrhage. If the cause of bleeding is removed by surgery, intravenous infusion of this product should be continued for at least 5 days after surgery. Therapeutic medication: If ischemic neurological dysfunction caused by vasospasm has occurred after subarachnoid hemorrhage, treatment should be started as soon as possible and should last for at least 5 days and up to 14 days. Medication for ischemic cerebrovascular disease: 4-10 mg/time, once/day, or as directed by a doctor.

A large number of clinical practices have shown that about 11.2% of patients with subarachnoid hemorrhage experience adverse reactions when treated with nimodipine. The most common adverse reactions are: 1. Decreased blood pressure, the degree of which is related to the drug dose. 2. Hepatitis. 3. Skin tingling. 4. Gastrointestinal bleeding. 5. Thrombocytopenia. 6. Occasionally transient dizziness, headache, facial flushing, vomiting, gastrointestinal discomfort, etc. In addition, some patients may experience increased levels of alkaline phosphatase (ALP), lactate dehydrogenase (LDH), increased blood sugar, and increased platelet count in some individuals.

Not yet clear.

(1) When used in combination with other calcium ion antagonists that act on the cardiovascular system, it can increase the effectiveness of other calcium ion antagonists. (2) When nimodipine 90 mg/day is used in combination with cimetidine 1000 mg/day for more than one week, the blood concentration of nimodipine can increase by 50%, which may be related to the fact that cimetidine inhibits cytochrome P450 in the liver and blocks the metabolism of nimodipine.

Keep in a light-proof and airtight container.

4 mg

Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd.

• Founded in:

  1993-07-05

• Address:

  The First Pharmaceutical Park, Economic and Technological Development Zone, Datong City, Shanxi Province

• Tax NO.:

  91140200602165291J

• Registered Funds:

  395 million yuan

• Website:

  Log in to view

• Email:

  Log in to view